Ground-breaking Cancer, Parkinson’s Research Team Given Five-year Funding Boost

Dundee-based researchers with a track record of devising treatments for deadly diseases like cancer and Parkinson’s – whose work has crowded in £60 million in investment to date – are receiving further backing from the government to continue their vital work for a further five years, Science and Technology Secretary Peter Kyle will announce Thursday. 

The Medical Research Council’s Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) will receive nearly £30 million of funding allocated from UKRI’s Medical Research Council (MRC) to bolster its cell biology research centre as it continues its vital work over the next 5 years. 

Currently, the 200-strong scientific community of staff and students based at the University of Dundee are using cutting-edge technology and biochemistry to explore how signals transmitted within the body’s cells are disrupted. Working closely with industry, Dundee’s unit has been a fundamental part of the development and clinical approval of over 40 drugs that are now widely used to treat patients, attracting almost £60 million in private investment.

It is just one example cementing Scotland’s place at the forefront of the UK government’s plans to make Britain a powerhouse for life sciences that attracts international investment and drives forward the deployment of discoveries that grow the economy, create prosperity across the country and improve lives and public services.

Improving our understanding of the processes within cells could be the key to unlocking the scientific basis of innovative treatments for a range of diseases – from Alzheimer’s and Parkinson’s to Crohn’s and coeliac disease.  Their work has already delivered a drug that is now widely used to treat skin cancer.

The new funding comes ahead of the Science and Technology Secretary addressing higher education representatives at the Universities UK conference at the University of Reading, where he will reflect on his personal experience in higher education and will give his full-throated backing to the sector as a vehicle for much-needed economic growth.  

He will also outline his vision for DSIT, and the crucial role universities can play in this, harnessing discoveries and innovations for novel therapies and technologies, like those developed in Dundee, that could transform patients’ lives and drive economic growth.

Working with other companies, including GlaxoSmithKline, the team was central to developing a drug now widely used to treat melanoma, and a promising new drug for Parkinson’s disease is in clinical trials as a result of the team’s globally recognise work, investigating the condition to discover potential causes and treatments. 

Universities are vital to the government’s mission to boost our economy and transform healthcare services with world-class science and research. They are at the heart of our research strengths, underpinning key sectors including life sciences. Backing university-based researchers, like the team at the University of Dundee, will ensure that they can continue unlocking the technologies and therapies that could be life-changing to patients, and which drive economic growth and productivity.